Overview

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Status:
Not yet recruiting

Trial end date:
2027-07-01

Target enrollment:

Participant gender:

Summary

This is an open, prospective, multi-center, single-arm phase II clinical study assessing the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin in patients with pMMR/MSS locally advanced middle and low rectal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Beijing Friendship Hospital

Collaborator:

Peking Union Medical College Hospital

Treatments:

Capecitabine
Thymalfasin
Tislelizumab